Homo obesus: A metabotrophin-deficient species. Pharmacology and nutrition insight

Current Pharmaceutical Design

Volumn 13, Issue 21, 2007, Pages 2176-2179

  Chaldakov, G N ^a   Fiore, M ^b   Tonchev, A B ^a   Dimitrov, D ^a   Pancheva, R ^a   Rancic, G ^c   Aloe, L ^b  

^a MEDICAL UNIVERSITY OF VARNA   (Bulgaria)

^b EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^c Medical Faculty   (Serbia)

Author keywords

Metabotrophin targeted pharmacology; Metabotrophins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; IBUDILAST; INCRETIN; INTERLEUKIN 10; LIPID; METABOTROPHIN; NERVE GROWTH FACTOR; NEUROTROPHIN; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PYCNOGENOL; REPAGLINIDE; RESVERATROL; SIRTUIN; UNCLASSIFIED DRUG;

CALORIC RESTRICTION; ENERGY; EPIDEMIC; GLUCOSE HOMEOSTASIS; HUMAN; INFLAMMATION; NONHUMAN; NUTRITION; OBESITY; PATHOGENESIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; WOUND HEALING;

BRAIN-DERIVED NEUROTROPHIC FACTOR; CALORIC RESTRICTION; ENERGY METABOLISM; GLUCOSE; HUMANS; LIPID METABOLISM; NERVE GROWTH FACTOR; NUTRITION PHYSIOLOGY; OBESITY; STILBENES;

EID: 34447529335     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781039616     Document Type: Review

References (59)

1. Lean M, Lara J. O'Hill J. ABC of obesity. Strategies for preventing obesity. BMJ 2006; 333: 959-62.
2. Aloe L, Calza L, editors. NGF and Related Molecules in Health and Disease. Elsevier Science B.V.: Amsterdam. Prog Brain Res 2004; 146: 3-527.
3. Chaldakov GN, Fiore M, Hristova M, Aloe L. Metabotrophic potential of neurotrophins: implication in obesity and related diseases. Med Sci Monit 2003; 21: H19-21.
4. Chaldakov GN, Fore M, Tonchev AB, Aloe L. Adipopharmacology, a novel drug discovery approach. A metabotrophic perspective. Lett Drug Des Discov 2006; 3: 503-5.
5. Chaldakov GN, Stankulov IS, Hristova M, Ghenev PI. Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr Pharm Des 2003; 9: 1023-31.
6. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347-55.
7. Chaldakov GN, Fiore M, Stankulov IS, Manni L, Hristova MG, Antonelli A, et al. Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease? Prog Brain Res 2004; 146: 279-89.
8. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005; 2: 536-43.
9. Frühbeck G. Vasoactive factors and inflammatory mediators produced in adipose tissue. In: Fantuzzi G, Mazzone T, editors. Health and Nutrition. Adipose Tissue and Adipokines in Health and Disease. Humana Press Inc., Totowa, NJ, USA 2006; 61-75.
10. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3: 35-42.
11. Chaldakov GN, Tonchev AB, Tuncel N, Atanassova P, Aloe L. Adipose tissue and mast cells. Adipokines as yin-yang modulators of inflammation. In: G. Fantuzzi, T. Mazzone, editors. Nutrition and Health: Adipose Tissue and Adipokines in Health and Disease. Humana Press Inc., Totowa, NJ. 2006; Chapter 12, pp. 147-54.
12. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006; 74: 443-77.
13. Xu A, Laam MC, Chan KW, Wang Y, Zhang J, Hoo RLC, et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci USA 2005; 102: 6086-91.
14. Chaldakov GN, Tonchev AB, Georgieva Z, Ghenev PI, Stankulov IS. Adipobiology of inflammation. Biomed Rev 2005; 16: 83-8.
15. Beltowski J. Apelin and visfatin: Unique "beneficial" adipokines upregulated in obesity? Med Sci Monit 2006; 12: RA112-9.
16. Sjogren M, Blennow K. The link between cholesterol and Alzheimer's disease. World J Biol Psychiatry 2005; 6: 85-97.
17. Sun MK, Alkon DL. Links between Alzheimer's disease and diabetes. Drugs Today (Barc) 2006; 42: 481-9.
18. Manni L, Nikolova V, Vyagova D, Chaldakov GN, Aloe L. Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. Int J Cardiol 2005; 102: 169-71.
19. Nakagawa T, Ogawa Y, Ebihara K, Yamanaka M, Tsuchida A, Taiji M, et al. Anti-obesity and anti-diabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistance. Int J Obes Relat Metab Disord 2003; 27: 557-65.
20. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007; 50: 431-8.
21. Geroldi D, Minoretti P, Emanuele E. Brain-derived neurotrophic factor and metabolic syndrome: More than just a hypothesis. Med Hypotheses 2006; 67: 195-6.
22. Aloe L, Levi-Montalcini R. Mast cell increase in tissues of neonatal rats injected with the nerve growth factor. Brain Res 1977; 133: 358-66.
23. Fainzilber M, Carter BD. From neurotrophins to immunotrophins. EMBO Rep 2002; 3: 1029-34.
24. Botchkarev VA, Botchkareva NV, Peters EMJ, Paus R. Epithelial growth control by neurotrophins: leads and lessons from the hair follicle. Prog Brain Res 2004; 146: 493-513.
25. Gray J, Yeo G, Hung C, Keogh J, Clayton P, Banerjee K, et al. Functional characterization of human NTRK2 mutations identified in patients with severe early-onset obesity. Int J Obes 2006; 16 May.
26. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006; 60: 1454-70.
27. Gallwitz B. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva Endocrinol 2006; 31: 133-47.
28. Cheng KKY, Lam KSL, Wang Y, Xu A. Adiponectin as a key player in inflammation. Biomed Rev 2006; 17: 11-22.
29. Plosker GL, Figgitt DP. Repaglinide: a pharmacoeconomic review of its use in type 2 diabetes mellitus. Pharmacoeconomics 2004; 22: 389-411.
30. Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 2004; 46: 404-11.
31. Miggiano GA, De Sanctis R. Nutritional genomics: toward a personalized diet. Clin Ter 2006; 157: 355-61.
32. Dimitrov D, Pancheva R, Tonchev AB, Koseva K, Kostov D, Georgieva J, et al. Nutrigenomics: DNA-based individualized diet. Biomed Rev 2006; 17: 117-22.
33. Picard F, Guarente L. Molecular links between aging and adipose tissue. Int J Obesity (Lond) 2005; 29 (Suppl 1): S36-9.
34. Guarente L, Picard F. Calorie restriction - the SIR2 connection. Cell 2005; 120: 473-82.
35. Lamming DW, Wood JG, Sinclair DA. Small molecules that regulate lifespan: evidence for xenohormesis. Mol Microbiol 2004; 53: 1003-9.
36. Yun AJ, Lee PY, Doux JD. Are we eating more than we think? Illegitimate signaling and xenohormesis as participants in the pathogenesis of obesity. Med Hypotheses 2006; 67: 36-40.
37. Trapp J, Jung M. The role of NAD+ dependent histone deacetylases (sirtuins) in ageing. Curr Drug Targets 2006; 7: 1553-60.
38. Anekonda TS, Reddy PH. Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem 2006; 96: 305-13.
39. Anekonda TS. Resveratrol - a boon for treating Alzheimer's disease? Brain Res Brain Res Rev 2006; 52: 316-26.
40. Corder R, Mullen W, Khan NO, Marks SC, Wood EG, Carrier MJ, et al. Oenology: red wine procyanidins and vascular health. Nature 2006; 444 (7119): 566.
41. Mattson MP. Energy intake, meal frequency, and health: A neurobiological perspective. Annu Rev Nutr 2005; 25: 237-60.
42. Flachs P, Mohamed-Ali V, Horakova D, Rossmeisl M, Hosseinzadeh-Attar MJ, Hensler M, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 2006; 49: 394-7.
43. Gulati OP. The nutraceutical Pycnogenol: its role in cardiovascular health and blood glucose control. Biomed Rev 2005; 16: 49-57.
44. Benga G. Aquaporin7 and adipose tissue. Biomed Rev 2006; 17: 105-10.
45. Fruhbeck G, Catalan V, Gomez-Ambrosi J, Rodriguez A. Aquaporin-7 and glycerol permeability as novel obesity drug-target pathways. Trends Pharmacol Sci 2006; 27: 345-7.
46. Rodriguez A, Catalan V, Gomez-Ambrosi J, Fruhbeck G. Role of AQP7 in the pathophysiological control of fat accumulation in mice. FEBS Lett 2006; 580: 4771-6.
47. Cai D, Holm JM, Duignan IJ, Zheng J, Xaymardan M, Chin A, et al. BDNF-mediated enhancement of inflammation and injury in the aging heart. Physiol Genomics 2006; 24: 191-7.
48. Ejiri J, Inoue N, Kobayashi S, Shiraki R, Otsui K, Honjo T, et al. Possible role of brain-derived neurotrophic factor in the pathogenesis of coronary artery disease. Circulation 2005; 112: 2114-20.
49. Suwa M, Kishimoto H, Nofuji Y, Nakano H, Sasaki H, Radak Z, et al. Serum brain-derived neurotrophic factor level is increased and associated with obesity in newly diagnosed female patients with type 2 diabetes mellitus. Metab Clin Exp 2006; 55: 852-7.
50. Watson RT, Kanzaki M, Pessin JE. Regulated membrane trafficking of the insulin-responsive glucose transporter 4 in adipocytes. Endocr Rev 2004; 25: 177-204.
51. Kontani Y, Wang Y, Kimura K, Inokuma KI, Saito M, Suzuki-Miura T, et al. UCP1 deficiency increases susceptibility to diet-induced obesity with age. Aging Cell 2005; 4: 147-55.
52. Inokuma K, Okamatsu-Ogura Y, Omachi A, Matsushita Y, Kimura K, Yamashita H, et al. Indispensable role of mitochondrial UCP1 for antiobesity effect of beta-3-adrenergic stimulation. Am J Physiol Endocrionol Metab 2006; 290: E1014-21.
53. Kalra SP, Kalra PS. Gene-trasnfer technology: a preventive neurotherapy to curb obesity, ameliorate metabolic syndrome and extend life expectancy. Trends Pharmacol Sci 2005; 26: 488-95.
54. del Porto F, Aloe L, Lagana B, Triaca V, Nofroni I, D'Amelio R. NGF and BDNF levels in patients with rheumatoid arthritis treated with TNF-α blockers. Ann NY Acad Sci 2006; 1069: 438-43.
55. Bocsi J, Mittag A, Sack U, Gerstner AO, Barten MJ, Tarnok A. Novel aspects of systems biology and clinical cytomics. Cytometry A 2006; 69: 105-8.
56. Keusch GT. What do -omics mean for the science and policy of the nutritional sciences? Am J Clin Nutr 2006; 83: 520S-2S.
57. Guido M, Romualdi D, Lanzone A. Role of opioid antagonists in the treatment of women with glucoregulation abnormalities. Curr Pharm Des 2006; 12(8): 1001-12.
58. Jaumdally JR, Lip GY, Varma C. Traditional risk factors for coronary atherosclerosis in Indo Asians: the need for a reappraisal. Curr Pharm Des 2006; 12(13): 1611-21.
59. Roth BL, Kroeze WK. Screening the receptorome yields validated molecular targets for drug discovery. Curr Pharm Des 2006; 12(14): 1785-95.